Ignite Creation Date:
2024-05-05 @ 6:32 PM
Last Modification Date:
2024-10-26 @ 9:34 AM
Study NCT ID:
NCT00494325
Status:
COMPLETED
Last Update Posted:
2018-05-03
First Post:
2007-06-27
Brief Title:
The Role of Macular Pigment in Patients With Age-related Macular Degeneration
Sponsor:
Insel Gruppe AG University Hospital Bern
Organization:
Insel Gruppe AG University Hospital Bern
Study Overview
Official Title:
The Role of Macular Pigment in Patients With Age-related Macular Degeneration
Status:
COMPLETED
Status Verified Date:
2018-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In the industrialised world age-related macular degeneration ARMD is the leading cause for legal blindness beyond the age of 50 years Recent studies indicate that the amount and status of the macular pigment MP may play a central role in the development and progression of the disease It has been demonstrated that the MP density can be increased by dietary supplementation First results of MP density measurements with a modified confocal laser scanning ophthalmoscope show that this method allows to quantify the MP in a clinical setting The aim of this study is to assess the peak MP density as well as the MP distribution in relation to the risk for ARMD We will establish reference values for MP density distribution in a normal population and compare these to values obtained from patients with age related maculopathy in a cross-sectional study For all MP density measurements we will use a modified scanning laser ophthalmoscope and dietary intake of macular pigment will be assessed using a Food Frequency Questionnaire Clinical examinations will include ETDRS visual acuity binocular ophthalmoscopy colour fundus photography and autofluorescence imaging The results of our study will help assess the relationship of macular pigment density and distribution with ARMD Additionally we will be able to identify patients with low MP density and probably improve the early diagnosis of patients at high risk for developing ARMD This will be the basis for dietary supplementation of lutein andor zeaxanthin in patients with high risk for ARMD due to low macular pigment values
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| SNF 3200 Bo-1099621 | OTHER_GRANT | SNF | None |